Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IXin vitro. Comparison between human glioblastoma cells and other cancer cell lines

2007 ◽  
Vol 6 (2) ◽  
pp. 145-151 ◽  
Author(s):  
Reinhard Sailer ◽  
Wolfgang S. L. Strauss ◽  
Michael Wagner ◽  
Helmut Emmert ◽  
Herbert Schneckenburger
2009 ◽  
Vol 43 (12) ◽  
pp. 1214-1224 ◽  
Author(s):  
Shinji Ito ◽  
Norio Miyoshi ◽  
William G. Degraff ◽  
Kunio Nagashima ◽  
Louis J. Kirschenbaum ◽  
...  

Author(s):  
Priyankar Maji ◽  
Ranodeep Chatterjee ◽  
Biswa P. Choudhury ◽  
Urmi Chatterji ◽  
Jhuma Ganguly

Objective: This study was designed to analyze the combinatorial chemotherapeutic effect of temozolomide (TMZ), the most common drug in glioblastoma treatment and a purified carbohydrate (Fr-II) from the edible mushroom Pleurotus florida, on human glioblastoma cell lines.Methods: Fr-II was purified by size-exclusion chromatography and characterised by different mass spectroscopy analysis. Human glioblastoma cells were treated with TMZ, Fr-II, and combination of TMZ and Fr-II. Cell cytotoxicity was measured by MTT assay, cell cycle phase distribution was determined by cell cycle analysis and followed by the relative p53 protein expression was analyzed by western blot analysis.Results: Chemical analysis of Fr-II confirmed the glycosidically linked two units of glucose with terminally attached mannitol with mass of 506 Da. Fr-II treatment exhibited cytotoxicity in both the cell lines in a dose-dependent manner with most effective dose at 200µg/ml. When Fr-II (200µg/ml) was combined with a dose range of TMZ it showed a more cellular cytotoxicity compared to the cytotoxicity of TMZ alone with most oppressive combinatorial dose at 400µM (TMZ)+200µg/ml (Fr-II). In compliance, with the above results, both cell lines showed a 10% increase in no. of cells (p<0.05) in G2/M phase indicating an arrest of cell cycle and increased p53 protein expression (p<0.05) at the combinatorial dose than TMZ alone at 400µM, but Fr-II alone didn’t show any cell cycle arrest nor did it show increased p53 expression.Conclusion: Therefore it confirms that Fr-II synergizes with TMZ to significantly intensify its anti-proliferative properties, thereby emerging as an effective element for combinatorial treatment of glioblastoma.


Author(s):  
Yihao Zhu ◽  
Handong Wang ◽  
Maoxing Fei ◽  
Ting Tang ◽  
Wenhao Niu ◽  
...  

AbstractSmarcd1 is a component of an evolutionary conserved chromatin remodeling complex—SWI/SNF, which is involved in transcription factor recruitment, DNA replication, recombination, and repair. Suppression of the SWI/SNF complex required for cellular differentiation and gene regulation may be inducible for cell proliferation and tumorigenicity. However, the inhibitory role of Smarcd1 in human glioblastoma cells has not been well illustrated. Both U87 and U251 human glioblastoma cell lines were employed in the present study. The lentivirus-mediated gene knockdown and overexpression approach was conducted to determine the function of Smarcd1. The protein levels were tested by western blot, and the relative mRNA contents were detected by quantitative real-time PCR. Cell viability was tested by CCK-8 and colony-forming assay. Transwell assays were utilized to evaluate the motility and invasive ability. Flow cytometry was employed to analyze cell cycle and apoptosis. SPSS software was used for statistical analysis. Low expression of Smarcd1 was observed in glioblastoma cell lines and in patients with high-grade glioma. Importantly, the depletion of Smarcd1 promoted cell proliferation, invasion, and chemoresistance, whereas enhanced expression of Smarcd1 inhibited tumor-malignant phenotypes. Mechanistic research demonstrated that overexpression of Smarcd1 decreased the expression of Notch1, while knockdown of Notch1 increased the expression of Smarcd1 through Hes1 suppression. Hence, the crosstalk between Smarcd1 and Notch1, which formed a feedback loop, was crucial in regulation of glioblastoma malignant phenotypes. Furthermore, targeting Smarcd1 could be a potential strategy for human glioblastoma treatment.


2011 ◽  
Vol 81 (5) ◽  
pp. 606-616 ◽  
Author(s):  
Isabelle Coupienne ◽  
Sébastien Bontems ◽  
Michael Dewaele ◽  
Noemi Rubio ◽  
Yvette Habraken ◽  
...  

2014 ◽  
Vol 79 (3) ◽  
pp. 422-431 ◽  
Author(s):  
Taku Chibazakura ◽  
Yui Toriyabe ◽  
Hiroshi Fujii ◽  
Kiwamu Takahashi ◽  
Mariko Kawakami ◽  
...  

Author(s):  
Viktorija Herceg ◽  
Norbert Lange ◽  
Eric Allémann ◽  
Andrej Babič

1999 ◽  
Author(s):  
Sonja Fickweiler ◽  
Rene C. Krieg ◽  
Herbert G. Stepp ◽  
Ferdinand Hofstaedter ◽  
Ruth Knuechel

Sign in / Sign up

Export Citation Format

Share Document